Why the study?
Does cilostazol prevent secondary ischemic stroke compared to other antiplatelets in patients with ischemic stroke?
Does cilostazol prevent secondary ischemic stroke compared to other antiplatelets in patients with ischemic stroke?
Cilostazol is highlighted as a promising, safe, and effective alternative to traditional antiplatelets for secondary stroke prevention.
No takes yet. Share an insight, caveat, or question.
May support cilostazol as alternative for secondary stroke prevention; leaves open need for head-to-head RCTs.
Al-Qudah et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: